Lipid Signature May Flag Schizophrenia

A specific lipid profile can identify patients with schizophreniapossibly paving the way for the development of the first clinically useful diagnostic test for a severe psychiatric illness, new research suggests. Although such a test remains a long way off, investigators said, the identification of the unique lipid signature is a critical first step. However, one … Read more

PCSK9 Inhibitors for Severe COVID? Pilot Trial Signals Benefit

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. PCSK9 inhibitors may best be known for their powerful LDL-lowering effects but are less appreciated as anti-inflammatory agents with potential beyond cardiovascular health. In a small pilot trial, for example, patients hospitalized with severe COVID-19 who received a single injection of … Read more

High Lipoprotein(a) Levels Plus Hypertension Add to CVD Risk

High levels of lipoprotein(a) increase the risk for incident cardiovascular disease (CVD) for hypertensive individuals but not for those without hypertensiona new MESA analysis suggests. There are ways to test for statistical interaction, “in this case, multiplicative interaction between Lp(a) and hypertension, which suggests that Lp(a) is actually modifying the effect between blood pressure and … Read more

The Ins and Outs of Inclisiran

This transcript has been edited for clarity Christopher V. DeSimone, MD, PhD: Hello. Welcome back to the Mayo Clinic Medscape video series. I’m Christopher DeSimone, electrophysiologist here at Mayo Clinic. Today, we’ll be discussing lipid management and inclisiran, specifically. I’m joined by my colleague Stephen Kopecky, preventive cardiologist and professor of medicine at Mayo Clinic. … Read more